Department of Obstetrics & Gynecology.
Department of Anesthesiology.
Medicine (Baltimore). 2020 Dec 11;99(50):e23651. doi: 10.1097/MD.0000000000023651.
Tocolytic agents, commonly used for inhibiting preterm labor, pose the risk of uterine atony, leading to postpartum hemorrhage. This study elucidated the effects of different tocolytic agents on postoperative hemorrhage among women in preterm labor undergoing Cesarean delivery (CD). Data from Taiwan National Health Insurance Research Database were analyzed. The risk (adjusted hazard ratio [aHR] and 95% confidence intervals [CI]) of postoperative hemorrhage in CD women with preterm labor diagnosis using tocolytic agents (Tocolysis group) comparing to CD women not using tocolytic agents (Control group) were determined. Impacts of different tocolytic agents in this regard were also investigated. Our data revealed that the incidence (11.7% vs 2.6%, P < .001) and risk (aHR: 1.21, 95% CI: 1.12-1.31, P < .001) of postoperative hemorrhage were significantly higher in the Tocolysis group (n = 15,317) than in the Control group (n = 244,096). Ritodrine was the most frequently used tocolytic agent (80.5%), followed by combination therapy (using more than one tocolytic agents) (8.5%), magnesium sulfate (MgSO4, 4.6%), calcium channel blockers (3.8%), betamimetics other than ritodrine (1.9%), prostaglandin synthase inhibitors (0.5%), and nitrates (0.1%). Barring those using calcium channel blockers and combination therapy, the use of MgSO4 (aHR: 1.43, P = .001), betamimetics other than ritodrine (aHR: 1.71, P < .001), prostaglandin synthase inhibitors (aHR: 2.67, P < .001) and nitrates (aHR: 3.30, P = .001) was associated with higher risks of postoperative hemorrhage compared with ritodrine. In conclusion, CD women with preterm labor diagnosis using tocolytic agents exhibit an increased risk of postoperative hemorrhage and that this risk varies with the use of different tocolytic agents.
促胎肺成熟药物常用于抑制早产,但会导致子宫乏力,引起产后出血。本研究旨在探讨不同的保胎药物对剖宫产(CD)中早产孕妇术后出血的影响。本研究使用台湾全民健康保险研究数据库的数据进行分析。比较使用保胎药物(保胎组)与未使用保胎药物(对照组)的 CD 中早产孕妇的术后出血风险(调整后的风险比[aHR]和 95%置信区间[CI])。同时还研究了不同保胎药物的影响。我们的数据显示,保胎组(n=15317)的术后出血发生率(11.7% vs 2.6%,P<.001)和风险(aHR:1.21,95%CI:1.12-1.31,P<.001)明显高于对照组(n=244096)。利托君是最常用的保胎药物(80.5%),其次是联合治疗(使用一种以上的保胎药物)(8.5%)、硫酸镁(4.6%)、钙通道阻滞剂(3.8%)、利托君以外的β受体激动剂(1.9%)、前列腺素合成酶抑制剂(0.5%)和硝酸盐(0.1%)。除了使用钙通道阻滞剂和联合治疗的患者外,硫酸镁(aHR:1.43,P=.001)、利托君以外的β受体激动剂(aHR:1.71,P<.001)、前列腺素合成酶抑制剂(aHR:2.67,P<.001)和硝酸盐(aHR:3.30,P=.001)的使用与术后出血风险增加相关。总之,使用保胎药物的 CD 中诊断为早产的孕妇术后出血风险增加,且这种风险因使用不同的保胎药物而异。